Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Phase I Arm A · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Phase I Arm A | EXPERIMENTAL | Dose escalation and expansion arm |
| Phase I Arm B | EXPERIMENTAL | Dose escalation and expansion arm |
| Name | Type | Description |
|---|---|---|
| Phase I Arm A | DRUG | Dose escalation and expansion arm, with protocol-defined dose(s) of GDC-7035 |
| Phase I Arm B | DRUG | Dose escalation and expansion arm, with protocol-defined dose(s) of GDC-7035 in combination with other anti-cancer therapies |
Inclusion Criteria: * Histologically documented advanced or metastatic solid tumor with KRAS G12D mutation * Agreement to adhere to the contraception requirements described in the protocol for participants of childbearing potential and participants who produce sperm Exclusion criteria: * Malabsor...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
Phase I Arm A is an investigational small molecule being studied for the treatment of solid tumors. It is currently in Phase 1 clinical development, meaning it has not been approved by regulatory authorities and is still being evaluated for safety and efficacy in patients.
Phase I Arm A is being developed by Roche Holding AG, which trades under the ticker RHHBY. The company is conducting clinical trials to evaluate the drug's safety, pharmacokinetics, and activity in patients with advanced solid tumors.
Phase I Arm A is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA or any other regulatory agency. The ongoing trial is recruiting participants to assess the drug's safety, pharmacokinetics, and preliminary activity.
Phase I Arm A is being studied in a single Phase 1 clinical trial with the identifier NCT06619587. This trial is recruiting 410 patients with solid tumors across multiple countries, including the United States, Australia, Canada, France, Israel, Italy, Singapore, South Korea, Spain, and the United Kingdom.
Phase I Arm A is an arm of a clinical trial evaluating the investigational drug GDC-7035. The trial, NCT06619587, studies GDC-7035 as a single agent and in combination in patients with advanced solid tumors. Phase I Arm A refers to a specific treatment group within this trial.